OPN-5877 / Opna Bio - LARVOL DELTA

Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity (ASH 2025) - P1 | "OPN-6602 is a potent oral small molecule inhibitor of the BRDs of EP300and CBP that is currently in a Phase 1 clinical study to evaluate efficacy and safety in patients withrelapsed/refractory MM (NCT06433947).Preclinical MM studies that combine IMiDs with OPN-6602 demonstrate synergy with high xenografttumor response, including complete regressions and improved response durability (Matusow 2024). This set ofdata suggested that each molecule of OPN-5877 resulted in the degradation of many molecules of thetarget proteins.Further chemical optimization towards a development candidate is ongoing. This polypharmacologyapproach has potential to yield a novel therapeutic with multifunctional activity that targets severaloncogenic pathways concurrently in the same cancer cell, thus enabling effective single agent anti-canceractivity."

IO biomarker • Hematological Malignancies • Lymphoma • Multiple Myeloma • Targeted Protein Degradation • BCL2 • CRBN • CREBBP • EP300 • IKZF1 • IKZF3 • IRF4

Opna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program… (Businesswire) - "The oral presentation will feature preclinical data from Opna’s protein degrader program, which is focused on creating novel therapeutics designed to block multiple oncogenic targets - EP300, CBP, IKZF1 and IKZF3 - concurrently in the same cancer cell. The data highlights the preclinical compound’s potential for activity as a single agent in hematological malignancies such as multiple myeloma and lymphoma."

Preclinical • Lymphoma • Multiple Myeloma